<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990885</url>
  </required_header>
  <id_info>
    <org_study_id>BL-7010.01</org_study_id>
    <nct_id>NCT01990885</nct_id>
  </id_info>
  <brief_title>Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.</brief_title>
  <official_title>A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Systemic Exposure of Single Escalating Administrations and Repeated Administration of BL-7010 in Well-Controlled Celiac Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of different amounts of BL-7010 in single&#xD;
      oral administration and in repeated oral administration to well-controlled celiac patients.&#xD;
      Another purpose is to evaluate if BL-7010 is absorbed by the body or not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Systemic Exposure Of Single Escalating Administrations And Repeated Administration Of Bl-7010 In Well-Controlled Celiac Patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to 4 weeks from time of first administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Significant change from baseline in vital signs and 12-lead ECG parameters</measure>
    <time_frame>For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to 4 weeks from time of first administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Significant change from baseline in laboratory safety parameters</measure>
    <time_frame>For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to 4 weeks from time of first administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of BL-7010</measure>
    <time_frame>Over a 24 hour period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-7010</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <other_name>BL7010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged 18-75 years who have signed an informed consent form&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5-29.9, inclusive&#xD;
&#xD;
          -  Documented history of biopsy-proven celiac disease.&#xD;
&#xD;
          -  Adherence to a gluten-free diet for the last 6 months prior to randomization&#xD;
&#xD;
          -  TG2 and EMA antibody (IgA) negative&#xD;
&#xD;
          -  Women of childbearing potential and all men must agree to use an approved form of&#xD;
             contraception&#xD;
&#xD;
          -  Ability and willingness to understand and comply with study procedures and to give&#xD;
             written informed consent prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IgA deficiency.&#xD;
&#xD;
          -  History of IgE-mediated reactions to gluten.&#xD;
&#xD;
          -  Other food sensitivities or allergies.&#xD;
&#xD;
          -  Use of oral steroids, biologics, immunosuppressants or non-steroidal anti-inflammatory&#xD;
             drugs 6 months prior to entry (screening).&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Clinically significant, concomitant gastrointestinal disease.&#xD;
&#xD;
          -  Have clinically significant current or historical medical problems such as diabetes&#xD;
             mellitus, clinically significant cardiac arrhythmias, arteriosclerotic heart disease,&#xD;
             renal insufficiency or failure, autoimmune disease, history of malignant melanoma or&#xD;
             history of cancer (excluding basal cell carcinoma) within the past 5 years prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subjects receiving drugs or oral devices that, in the opinion of the Investigator,&#xD;
             possible ineffective treatment with these drugs/oral devices for a duration of two&#xD;
             weeks will put the subject at a medical risk&#xD;
&#xD;
          -  Uncontrolled complications of celiac disease.&#xD;
&#xD;
          -  Any other condition that in the opinion of the Investigator will place the subject at&#xD;
             risk or prevent protocol compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku MÃ¤ki, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FinnMedi Clinical Trial Center</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRST Clinical Research Services</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>November 17, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

